Table 1.
LncRNA-ZEB1-AS1 expression | p-value | |||
---|---|---|---|---|
Low | High | Total | ||
Total cases | 64 | 55 | 119 | |
Age (years) | ||||
≤60 | 31 | 32 | 63 | 0.082 |
>60 | 33 | 23 | 56 | |
Gender | ||||
Female | 33 | 17 | 50 | 0.521 |
Male | 31 | 38 | 69 | |
Tumor size | ||||
≤2 | 25 | 24 | 49 | 0.054 |
>2 | 39 | 31 | 70 | |
Histological grade | ||||
High/Moderate | 20 | 23 | 43 | 0.002** |
Low | 44 | 32 | 76 | |
TNM stage | ||||
I~II | 37 | 28 | 54 | 0.313 |
III~IV | 27 | 27 | 65 | |
Lymphatic metastasis | ||||
Positive | 40 | 37 | 77 | 0.001** |
Negative | 24 | 18 | 42 | |
Vascular invasion | ||||
Positive | 37 | 30 | 67 | 0.169 |
Negative | 27 | 25 | 52 | |
Distant metastasis | ||||
Positive | 50 | 21 | 71 | 0.035* |
Negative | 14 | 34 | 48 |
Overexpression of lncRNA-ZEB1-AS1 was signifcantly associated with histological grade (P = 0.002), lymphatic metastasis (P = 0.001) and distant metastasis (P = 0.035), but not with patients’ age (P = 0.082), gender (P = 0.521), tumor size (P = 0.054),TNM stage (P = 0.313) and vascular infltration P = 0.169). The p-value represents the comparison between groups (*p < 0.05, **p < 0.01).